Positive Phase III results with Eklira (Almirall) published in COPD journal

New Phase IIIb data demonstrates comparable efficacy for twice-daily Eklira Genuair (aclidinium bromide), from Almirall, vs tiotropium following the 6-week study. The data show significant improvements in 24-hour bronchodilation for aclidinium vs placebo from day 1 of treatment. Significant improvements in bronchodilation vs tiotropium were found on day 1 with comparable bronchodilation vs tiotropium at week 6. In addition, aclidinium was shown to provide statistically significant improvements in COPD symptoms throughout the morning, day and night, compared to placebo that were numerically greater than achieved with tiotropium.

Data are published in the journal COPD. See: "Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomised, controlled phase IIIb study." Beier J et al. COPD, 2013; 00:1�12, 2013